- Home
- Publications
- Publication Search
- Publication Details
Title
Highlights of the Latest Advances in Research on CDK Inhibitors
Authors
Keywords
-
Journal
Cancers
Volume 6, Issue 4, Pages 2224-2242
Publisher
MDPI AG
Online
2014-10-27
DOI
10.3390/cancers6042224
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 14-3-3 Binding to Cyclin Y contributes to cyclin Y/CDK14 association
- (2014) S. Li et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34
- (2014) Mi Hee Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
- (2014) Claire Fabre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
- (2014) B. Holkova et al. CLINICAL CANCER RESEARCH
- CR8, a Novel Inhibitor of CDK, Limits Microglial Activation, Astrocytosis, Neuronal Loss, and Neurologic Dysfunction after Experimental Traumatic Brain Injury
- (2014) Shruti V Kabadi et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)
- (2014) M. V. Ramana Reddy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
- (2014) K. Keegan et al. MOLECULAR CANCER THERAPEUTICS
- Cdk5 inhibitor roscovitine alleviates neuropathic pain in the dorsal root ganglia by downregulating N-methyl-d-aspartate receptor subunit 2A
- (2014) Lei Yang et al. NEUROLOGICAL SCIENCES
- Fragment based discovery of arginine isosteres through REPLACE: Towards non-ATP competitive CDK inhibitors
- (2013) Padmavathy Nandha Premnath et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A phase I trial of flavopiridol in relapsed multiple myeloma
- (2013) Craig C. Hofmeister et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
- (2013) Ivana Gojo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer
- (2013) Ulrich Lücking et al. ChemMedChem
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
- (2013) Agnese Anna Abate et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
- (2013) Mark A. Dickson et al. JOURNAL OF CLINICAL ONCOLOGY
- The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells
- (2013) Takuro Hayashi et al. JOURNAL OF NEURO-ONCOLOGY
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
- (2013) D Cirstea et al. LEUKEMIA
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
- (2013) Deborah M. Stephens et al. LEUKEMIA RESEARCH
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
- (2013) Kelly L. Barton et al. PLoS One
- Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
- (2012) Prithviraj Bose et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
- (2012) Da Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD
- (2012) Nikolay O. Bukanov et al. CELL CYCLE
- The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
- (2012) J. J. Luke et al. CLINICAL CANCER RESEARCH
- A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261
- (2012) Keith C. Bible et al. GYNECOLOGIC ONCOLOGY
- Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
- (2012) D. M. Stephens et al. HAEMATOLOGICA
- AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells
- (2012) Pavithra Raghavan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Effect of Mimetic CDK9 Inhibitors on HIV-1-Activated Transcription
- (2012) Rachel Van Duyne et al. JOURNAL OF MOLECULAR BIOLOGY
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
- (2012) J A Woyach et al. LEUKEMIA
- Chemistry and Biology of Fascaplysin, a Potent Marine-Derived CDK-4 Inhibitor
- (2012) S. B. Bharate et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis
- (2012) D. Subramaniam et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent kinase inhibitors move into Phase III
- (2012) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Prevention of Radiation-Induced Salivary Gland Dysfunction Utilizing a CDK Inhibitor in a Mouse Model
- (2012) Katie L. Martin et al. PLoS One
- Cyclin K goes with Cdk12 and Cdk13
- (2012) Jiri Kohoutek et al. Cell Division
- Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
- (2012) M Orzáez et al. Cell Death & Disease
- Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors
- (2011) Mei-Chu Lo et al. ANALYTICAL BIOCHEMISTRY
- Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells
- (2011) Venkata Mahidhar Yenugonda et al. BIOORGANIC & MEDICINAL CHEMISTRY
- First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors
- (2011) Caroline Corbel et al. Biotechnology Journal
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
- (2011) J. E. Karp et al. BLOOD
- A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
- (2011) Christophe Massard et al. CELL CYCLE
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
- (2011) B. Holkova et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- CR8, a Selective and Potent CDK Inhibitor, Provides Neuroprotection in Experimental Traumatic Brain Injury
- (2011) Shruti V. Kabadi et al. Neurotherapeutics
- A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer
- (2010) Houman M. Fekrazad et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
- (2010) W. Blum et al. HAEMATOLOGICA
- Cyclin D3/CDK11p58 Complex Involved in Schwann Cells Proliferation Repression Caused by Lipopolysaccharide
- (2010) Yinong Duan et al. INFLAMMATION
- A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
- (2010) Mark Andrew Dickson et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
- (2009) D. Rathkopf et al. CLINICAL CANCER RESEARCH
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Evolution of Cyclin-Dependent Kinases
- (2009) John H. Doonan et al. MOLECULAR BIOTECHNOLOGY
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
- A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer
- (2009) Richard D. Carvajal et al. PANCREATOLOGY
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
- (2008) M. A. Phelps et al. BLOOD
- An Unusual Member of the Cdk Family: Cdk5
- (2008) Fatema A. Dhariwala et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Phase I Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer
- (2008) Saby George et al. Clinical Lung Cancer
- Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors
- (2008) Pascal Loyer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More